more response to the historic FDA approval of neoadjuvant perjeta

[Lani]

http://2013researchtopractice.createsend1.com/t/ViewEmail/y/19EDD2979CADDDCC/9FE6FF52FCD6984446778398EADC2510

['lizbeth]

Lani, this is a treasure trove of information.

I find this comment intriguing - what does Dr. O’Shaughnessy know that the rest do not seem to be clued into?

I would use it most of the time in combination with trastuzumab/chemotherapy. The pCR rates are of high importance in ER-negative, HER2-positive disease, and pertuzumab clearly increases the rate for these patients. Patients with luminal B HER2-positive breast cancer also have improved outcomes when they achieve pCR, so pertuzumab will be of benefit to those patients also. Joyce O’Shaughnessy, MD Co-Director
Breast Cancer Research Program
Baylor-Charles A Sammons
Cancer Center
Texas Oncology
US Oncology
Dallas, Texas

This lady is sharp . . . and on the ball!


Also, the randomized TRYPHAENA trial showed similar pCR rates of about 60% to 70% when patients were assigned preoperatively to TCH with pertuzumab versus FEC followed by taxane/trastuzumab/pertuzumab. TCH/pertuzumab may become the standard toward the end of the year.